Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Simplify and Speed Up Your COVID-19 Testing Process with LabDash

ALBANY, OREGON – Concept Systems and WVT Laboratory have engineered LabDash, a web-based sample tracking system designed to simplify and speed up the COVID-19 testing process, and are excited to make it available to patients, private sponsors, providers and labs. LabDash has been key in WVT’s ability to have scaled to the highest volume COVID-19…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Pro AV Today on MarketScale.

Share
Simplify and Speed Up Your COVID-19 Testing Process with LabDash

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

ALBANY, OREGON – Concept Systems and WVT Laboratory have engineered LabDash, a web-based sample tracking system designed to simplify and speed up the COVID-19 testing process, and are excited to make it available to patients, private sponsors, providers and labs. LabDash has been key in WVT’s ability to have scaled to the highest volume COVID-19 testing lab in Oregon. LabDash also works with the Oregon Health Authority and others to provide fast and acurate COVID-19 testing results.

Quick and accurate testing is paramount to improved diagnosis and treatment of the disease and to generate more positive patient outcomes during the pandemic. LabDash makes this possible by simplifying the patient testing process; collection, receipt at the labs, result notification and reporting.

With individual accounts for patients, healthcare providers, sponsors and labs, LabDash has tailored interfaces for each and drastically reduces the complexity of data collection and reporting, while ensuring data accuracy and privacy throughout the process.

The lifecycle and test kit tracking process of LabDash looks like this:

  • The lab generates and assigns barcodes to providers, sponsors and individual patients who have requested tests. The lab is then empowered to follow their own standard procedures for test kit distribution.
  • Providers and sponsors facilitate testing as needed. Providers and patients enter the barcode and patient information to correlate the two when the sample is collected, and write the patient’s initials on the test tube.
  • When tests arrive back at the lab, lab technician scan each sample barcode into LabDash to mark the sample as “received.” The patient’s initials appear on the screen and the technician verifies that it matches what’s written on the test tube – no more manual entry of information.
  • After processing the samples, lab technicians upload the test results to LabDash. Providers and patients are notified that their results have been uploaded and can instantly view their results. A Clinical Lab Report PDF may be downloaded by providers and patients for reporting, travel, or proof of testing.
  • The lab has access to a full customizable, searchable breakdown of all data for reporting. This includes all patient information, sample collection data, provider information and sponsor information.
  • The lab can create custom transaction reports to monitor performance and throughput. User management and messaging tools also enable customer support.

The benefits of LabDash are clear. Because manual data entry is eliminated, data is more accurate and staff strain is reduced. In addition, paperless data collection and electronic data transfer helps support HIPAA compliance and security.

LabDash empowers easy management and tracking of COVID-19 test kits and simplified reporting and analytics, driving measurable benefits across the healthcare ecosystem.

To sign up today, click here.

###

About LabDash

LabDash simplifies and speeds up the entire COVID-19 testing process for patients, providers, private sponsors, and labs. LabDash was designed and built by Concept Systems in partnership with Willamette Valley Toxicology, with a focus on the entire testing lifecycle from patient sign-ups through testing and results reporting, to billing and invoicing. Concept Systems created an easy process to ensure that customers are able to use the system; Create an account, get a QR code, and show up at the testing site: it’s that easy.

Pro AV Today

Part of this channel

Pro AV Today

Pro AV news, trends, and expert voices for the AV industry

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512